Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours by Trarbach, Tanja, Schultheis, Beate, Gauler, Thomas C., Schneider, Vesile, Strumberg, Dirk, Eberhardt, Wilfried E. E., Le Scouiller, Stephanie, Marotti, Marcelo, Brown, Kathryn H., Drevs, Joachim

Get full text